SEC Form 4 · accession 0001209191-15-038051
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua S Boger
Director
Period of report
Apr 29, 2015
Accepted (ET)
May 1, 2015 · 5:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 29, 2015 | M | 1,300 | $17.16 | A | 387,584 | D | |
| Common Stock | Apr 29, 2015 | M | 10,400 | $35.64 | A | 397,984 | D | |
| Common StockF2,F3 | Apr 29, 2015 | S | 4,300 | $123.72 | D | 393,684 | D | |
| Common StockF3,F4 | Apr 29, 2015 | S | 4,700 | $124.64 | D | 388,984 | D | |
| Common StockF3,F5 | Apr 29, 2015 | S | 2,000 | $125.63 | D | 386,984 | D | |
| Common StockF3,F6 | Apr 29, 2015 | S | 700 | $126.66 | D | 386,284 | D | |
| Common Stock | holding | — | — | — | 13,286 | I | 401(k) | |
| Common StockF7 | holding | — | — | — | 122,700 | I | Common Stock held in trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F8 | $17.16 | Apr 29, 2015 | M | 1,300 | D | — | Jul 19, 2015 | Common Stock | 1,300 | 14,800 | D |
| Stock Option (right to buy)F8 | $35.64 | Apr 29, 2015 | M | 10,400 | D | — | Feb 1, 2016 | Common Stock | 10,400 | 406,400 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $123.72 (range $123.15 to $124.09).
- F3Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $124.64 (range $124.17 to $125.16).
- F5Open market sales reported on this line occurred at a weighted average price of $125.63 (range $125.21 to $126.17).
- F6Open market sales reported on this line occurred at a weighted average price of $126.66 (range $126.40 to $127.15).
- F7Common stock held in grantor retained annuity trusts.
- F8Fully vested.